HemaSphere (Jun 2022)

PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

  • S. Delimpasi,
  • H. Quach,
  • M. Cavo,
  • P. J. Ho,
  • C. H.-S. Lee,
  • A. Santoro,
  • R. Schots,
  • P. Vlummens,
  • D. H. Yoon,
  • S.-S. Yoon,
  • C. D. Santos,
  • D. Samineni,
  • J. Huang,
  • K. Wehrman,
  • U. Patil,
  • S. Sheikh,
  • M. A. Dimopoulos

DOI
https://doi.org/10.1097/01.HS9.0000850972.76878.85
Journal volume & issue
Vol. 6
pp. 1906 – 1907

Abstract

Read online

No abstracts available.